Legend Biotech (LEGN) Receivables - Net (2019 - 2025)

Legend Biotech (LEGN) has 7 years of Receivables - Net data on file, last reported at $13.1 million in Q4 2025.

• In Q4 2025, Receivables - Net rose 104.69% year-over-year to $13.1 million; the TTM figure through Dec 2025 stood at $13.1 million (up 104.69% YoY), while the FY2025 annual figure was $13.1 million, up 104.69% from the prior year.
• Receivables - Net improved to $13.1 million in Q4 2025, from $1.2 million in the prior quarter.
• Across five years, Receivables - Net topped out at $100.0 million in Q4 2023 and bottomed at $1967.0 in Q1 2021.
• A 5-year average of $15.7 million and a median of $2.4 million in 2021 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net surged 2564770.36% — and 2023, when it sank 99.89%.
• Year by year, Receivables - Net stood at $50.4 million in 2021, then sank by 99.82% to $90000.0 in 2022, then soared by 111056.67% to $100.0 million in 2023, then tumbled by 93.6% to $6.4 million in 2024, then jumped by 104.69% to $13.1 million in 2025.
• The last three Receivables - Net figures came in at $13.1 million (Q4 2025), $1.2 million (Q3 2025), and $27.6 million (Q2 2025), per Business Quant data.

Peer Comparison